Loading
Old version — revision 1
This is a fixed snapshot of Organoids, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/organoids.md — the filesystem corpus, unchanged. Not an edit.
Self-organizing tissue cultures grown from stem cells that reproduce some of the architecture and function of an organ, used mainly for disease modelling rather than transplantation.
Organoids are three-dimensional cell cultures, grown from stem cells, that self-organize into structures reproducing some of the cell types, spatial arrangement and function of a real organ. They are not miniature organs. A cerebral organoid has cortical layers and firing neurons but no blood supply, no immune cells, no thalamic input and no consistent body plan; an intestinal organoid has crypts and absorptive cells but no nerves and no microbiome. What makes them valuable is that they are human, three-dimensional, and generated in numbers large enough to screen against.
Two derivation routes dominate. The adult-stem-cell route takes tissue-resident stem cells — from an intestinal biopsy, say — and embeds them in a laminin-rich basement membrane gel with a defined cocktail of niche factors, typically including R-spondin, epidermal growth factor, and inhibitors of BMP and TGF-β signalling. The cells proliferate and spontaneously build crypt-villus architecture. These organoids are epithelial only, genetically stable, and can be passaged for years.
The pluripotent route starts from embryonic stem cells or from Induced pluripotent stem cells generated with the Yamanaka factors, and applies a timed sequence of differentiation cues that mimics embryonic patterning: germ-layer induction, then regional specification, then self-organization. This route produces organoids containing multiple germ layers, including neurons and glia, but is slower, more variable, and yields tissue of fetal maturity.
Both depend on a permissive matrix. The standard reagent is a basement-membrane extract derived from a mouse tumour line, which is chemically undefined and varies between lots. Replacing it with synthetic hydrogels of tuned stiffness and defined adhesion ligands has been a persistent goal, partly for reproducibility and partly because an undefined animal-derived product is a poor foundation for anything clinical. Matrix stripped from donor tissue, described in Decellularized scaffolds, is a third option that trades definition for biological fidelity.
The dominant applications are diagnostic and pharmacological rather than therapeutic.
Disease modelling. Organoids derived from a patient carry that patient's genome, which makes them a testbed for monogenic disease. Cerebral organoids from microcephaly patients were the first widely cited case; they have since been used to study Zika virus neurotropism, and organoids of intestine, lung, liver and kidney model cystic fibrosis, polycystic kidney disease and metabolic disorders.
Functional drug testing. The clearest clinical use is in cystic fibrosis. Rectal biopsy organoids from an individual patient swell in response to forskolin only if CFTR is functional, and the magnitude of swelling predicts response to CFTR modulator drugs.1 Health systems in the Netherlands have used this assay to grant access to expensive modulators for patients whose mutations are too rare to have been included in registration trials. This is personalised medicine in the literal sense: the test is run on the patient's own tissue rather than on a population average. Patient organoids were also among the first human tissues in which a disease mutation was corrected by CRISPR–Cas9, when the CFTR defect was repaired in intestinal organoids from cystic fibrosis patients and the corrected cultures regained function.2
Cancer biology. Tumour organoid biobanks preserve the genetic and histological diversity of patient tumours far better than immortalized cell lines, and are used for drug sensitivity screening and for studying resistance.
Toxicology. Liver, cardiac and kidney organoids and organ-on-chip devices are being adopted for safety screening, a shift encouraged by regulatory moves away from mandatory animal testing for some product classes.
| Dimension | Organoid | Organ-on-chip | Animal model |
|---|---|---|---|
| Species | Human | Human | Non-human |
| Self-organizing architecture | Yes | Imposed by device | Native |
| Perfusion | None | Engineered flow | Native circulation |
| Immune and neural input | Absent | Usually absent | Present |
| Throughput | High | Moderate | Low |
| Maturity of tissue | Fetal | Fetal to variable | Adult |
No vasculature. An organoid grows until diffusion fails, which for most tissue types means a diameter of a few hundred micrometres to a couple of millimetres before a necrotic core develops. This caps size, distorts internal gradients, and prevents the perfusion-dependent maturation that real organs undergo. Approaches include co-culture with endothelial cells, transplantation into a host animal so that host vessels invade, and assembly into printed vascular frameworks as described in Organ bioprinting.
Fetal maturity. Transcriptionally and functionally, most organoids resemble first- or second-trimester tissue. Cerebral organoids do not develop adult cortical identity, and analyses have reported that cells in cortical organoids carry a metabolic stress signature that impairs proper subtype specification, a caution against reading them as faithful models of the mature brain.3 Prolonged culture improves maturity slowly and unevenly.
Variability. Batch-to-batch and line-to-line differences are substantial, particularly for the pluripotent route, where the same protocol can yield organoids of different regional identity. This limits statistical power and complicates use as a screening platform.
Missing components. Organoids typically lack resident immune cells, vasculature, innervation and mechanical loading. Assembloids, in which separately patterned organoids are fused, restore some of what is missing — cortical and subpallial spheroids fused together permit interneuron migration to be observed directly — but the reconstruction is partial.
Cerebral organoids generate spontaneous electrical activity, and cultured long enough they produce synchronized network oscillations. One widely discussed report compared the developmental trajectory of these oscillations to electroencephalographic features seen in preterm infants, a comparison the authors themselves qualified and that other researchers regarded as an artefact of the analysis rather than evidence of anything experiential.
The mainstream position is that current brain organoids are extremely unlikely to be conscious. They lack sensory input, lack the thalamocortical loops that most theories of consciousness treat as necessary, lack a body to act on, and are structurally disorganized compared to a real cortex. That said, the question is not empty, because there is no accepted test. Assessing organoid sentience runs into exactly the problem described in Neural correlates of consciousness and Machine consciousness: behavioural evidence is unavailable and theory-based indicators disagree with one another. Ethicists have argued for developing criteria in advance rather than after a disputed result — an application of the Precautionary principle to a research programme rather than to a deployed technology — and professional guidance so far treats organoid work as requiring standard rather than special oversight while flagging the issue as one to revisit.4 The situation differs from Whole brain emulation, where the object under discussion is a model of a specific existing brain; an organoid is an anonymous piece of developing tissue with no history and no prior mental content.
Transplantation sharpens it. Human cortical organoids grafted into rat cortex have been shown to integrate into host circuits, respond to whisker stimulation, and drive learned behaviour, which raises questions about the moral status of the resulting chimeric animal rather than of the organoid alone.5 Related questions attach to Stem-cell-based embryo models, where the definitional problem is what counts as an embryo rather than what counts as a mind.
Terminology"Organoid" is used loosely. It covers epithelial-only cultures with strict lineage fidelity, multi-lineage constructs from pluripotent cells, and assemblies fused from several pieces. Claims about what organoids can do rarely generalize across these categories. Cell collectives that self-organize into forms with no organ counterpart, such as the frog-cell constructs described in Xenobots, fall outside the term entirely.
The therapeutic use of organoids is beginning at the margins, and it does not look like transplanting an organoid as such. An early Japanese trial has transplanted intestinal organoid-derived cells into the ulcerated bowel of patients with ulcerative colitis, using the culture as a way to expand a patient's own epithelium rather than as a structure. Pancreatic islet clusters grown from stem cells are built by comparable methods and have relieved insulin dependence in early type 1 diabetes trials. In both cases a few million cells placed in the right site do useful work, and the three-dimensional architecture that defines an organoid in the laboratory is largely incidental to the therapy.
The larger ambition, using organoids as building blocks for Lab-grown organs, depends on solving perfusion and maturation, the same two problems that limit Tissue engineering generally. Little in the current work is likely to bear on the Organ shortage within this decade. What organoids have already changed is the epistemics of human biology: for the first time, a laboratory can run a controlled experiment on human tissue of a specified genotype, repeatedly, without a patient in the room.
paperDekkers, J. F. et al. "A functional CFTR assay using primary cystic fibrosis intestinal organoids." Nature Medicine, 2013. ↩
paperSchwank, G. et al. "Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients." Cell Stem Cell, 2013.↩The correction was made in cultured stem cells taken from patients; nothing was returned to a patient, and no clinical benefit was tested.
paperBhaduri, A. et al. "Cell stress in cortical organoids impairs molecular subtype specification." Nature, 2020. ↩
paperFarahany, N. A. et al. "The ethics of experimenting with human brain tissue." Nature, 2018. ↩
paperRevah, O. et al. "Maturation and circuit integration of transplanted human cortical organoids." Nature, 2022.↩Human tissue grafted into newborn rats; the behavioural result is a property of the rat, and the paper makes no claim about organoid experience.